Technical Trend Overview and Price Movement
Pfizer Ltd. closed at ₹4,664.00 on 30 March 2026, down 0.83% from the previous close of ₹4,703.15. The intraday range saw a high of ₹4,755.00 and a low of ₹4,653.00, reflecting moderate volatility. The stock remains well below its 52-week high of ₹5,987.65, while comfortably above its 52-week low of ₹3,742.90. This price action, combined with the technical trend change from mildly bearish to bearish, suggests a growing downside momentum.
MACD and Momentum Indicators Signal Weakness
The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly chart and mildly bearish on the monthly chart. This indicates that the short-term momentum is weakening more sharply than the longer-term trend, which still shows some residual strength but is deteriorating. The bearish MACD crossover on the weekly timeframe confirms that sellers are gaining control, and the stock may face further downward pressure in the near term.
RSI and Bollinger Bands Reflect Market Sentiment
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in a neutral zone. This suggests that the stock is neither overbought nor oversold, leaving room for further directional movement. However, the Bollinger Bands are bearish on both weekly and monthly timeframes, indicating that price volatility is skewed towards the downside. The stock price is likely trading near the lower band, signalling increased selling pressure and potential continuation of the bearish trend.
Moving Averages and KST Confirm Downtrend
Daily moving averages are firmly bearish, with the stock trading below key averages such as the 50-day and 200-day moving averages. This technical setup reinforces the negative momentum and suggests that any rallies may be met with resistance. The Know Sure Thing (KST) indicator aligns with this view, showing bearish signals on the weekly chart and mildly bearish on the monthly chart, further confirming the downtrend.
Volume and Dow Theory Insights
Interestingly, the On-Balance Volume (OBV) indicator is bullish on both weekly and monthly charts, signalling that despite price declines, accumulation may be occurring. This divergence between price and volume could indicate that institutional investors are selectively buying at lower levels, potentially providing some support. However, Dow Theory shows no clear trend on either weekly or monthly timeframes, reflecting market indecision and the absence of a confirmed reversal.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Comparative Performance Against Sensex
Examining Pfizer’s returns relative to the Sensex reveals a mixed performance. Over the past week, Pfizer declined by 2.25%, underperforming the Sensex’s 1.27% drop. Over one month, Pfizer’s loss of 7.98% was slightly better than the Sensex’s 9.48% decline. Year-to-date, Pfizer has fallen 6.39%, outperforming the Sensex’s sharper 13.66% drop. Over the one-year horizon, Pfizer delivered a robust 17.59% gain, significantly outperforming the Sensex’s negative 5.18% return. The three-year return of 33.90% also surpasses the Sensex’s 27.63%, though over five and ten years, Pfizer’s 6.78% and 172.37% returns lag behind the Sensex’s 50.14% and 190.41%, respectively.
Mojo Score and Rating Update
MarketsMOJO assigns Pfizer a Mojo Score of 37.0, categorising it as a Sell with a recent downgrade from Hold on 29 December 2025. This downgrade reflects the deteriorating technical parameters and the cautious outlook on the stock’s near-term price action. The small-cap market cap grade further emphasises the stock’s vulnerability to volatility and sector-specific risks.
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Pfizer faces sector-wide challenges including regulatory scrutiny, patent expiries, and competitive pressures. The bearish technical signals align with broader sector headwinds, suggesting that investors should remain vigilant. However, the bullish volume trends hint at selective interest, possibly from long-term investors anticipating a turnaround.
Holding Pfizer Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
Pfizer Ltd.’s recent technical deterioration signals caution for investors. The bearish MACD, moving averages, and Bollinger Bands suggest that the stock may continue to face downward pressure in the short to medium term. The neutral RSI and bullish OBV divergence indicate that some accumulation is occurring, but this has yet to translate into a sustained price recovery.
Given the downgrade to a Sell rating and the small-cap classification, investors should weigh the risks carefully. Those with a higher risk tolerance might consider monitoring volume trends and potential technical reversals before initiating new positions. Conversely, more conservative investors may prefer to explore alternative stocks within the Pharmaceuticals & Biotechnology sector or broader market that exhibit stronger technical and fundamental profiles.
Summary of Key Technical Indicators:
- MACD: Weekly Bearish, Monthly Mildly Bearish
- RSI: Neutral on Weekly and Monthly
- Bollinger Bands: Bearish on Weekly and Monthly
- Moving Averages: Daily Bearish
- KST: Weekly Bearish, Monthly Mildly Bearish
- OBV: Bullish on Weekly and Monthly
- Dow Theory: No clear trend on Weekly and Monthly
Investors should continue to monitor Pfizer’s price action closely, particularly for any signs of trend reversal or confirmation of the bearish momentum. The stock’s relative performance against the Sensex and sector peers will also be critical in assessing its medium-term prospects.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
